{
  "meta": {
    "title": "14_Antiplatelet_And_Anticoagulant",
    "url": "https://brainandscalpel.vercel.app/14-antiplatelet-and-anticoagulant-1b0a3b07.html",
    "scrapedAt": "2025-11-30T06:59:42.619Z"
  },
  "questions": [
    {
      "id": 57522,
      "choices": [
        {
          "id": 227390,
          "text": "Iron dextran"
        },
        {
          "id": 227391,
          "text": "Darbopoietin alpha"
        },
        {
          "id": 227392,
          "text": "Oprelvekin"
        },
        {
          "id": 227393,
          "text": "Filgrastim (G-CSF)"
        }
      ],
      "text": "An old woman is required to receive 4 cycles of cancer chemotherapy. After her first cycle, she developed chemotherapy-induced thrombocytopenia. Then in the next cycle, it would be appropriate to give this patient",
      "unique_key": "Q9573590",
      "question_audio": null,
      "question_video": null,
      "map_id": 34905569,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Oprelvekin. Oprelvekin is a recombinant form of interleukin-11 (IL-11), which stimulates megakaryocyte proliferation and platelet production, making it the preferred treatment for chemotherapy-induced thrombocytopenia. Chemotherapy can cause bone marrow suppression, leading to reduced platelet production and an increased risk of bleeding. Oprelvekin helps mitigate this risk by enhancing thrombopoiesis, thereby reducing the need for platelet transfusions in subsequent chemotherapy cycles. It is particularly beneficial in patients requiring multiple chemotherapy cycles who develop significant thrombocytopenia after the first cycle. Incorrect Options: (A) Iron dextran: Iron dextran is used for iron deficiency anemia, not thrombocytopenia. While chemotherapy can cause anemia, this patient specifically has chemotherapy-induced thrombocytopenia, which is due to decreased platelet production, not iron deficiency. Thus, iron supplementation would not be beneficial. (B) Darbepoietin alpha: Darbepoietin alpha is a long-acting erythropoiesis-stimulating agent (ESA) used to treat chemotherapy-induced anemia by stimulating red blood cell production. However, it does not affect platelet production and would not be helpful for chemotherapy-induced thrombocytopenia. (D) Filgrastim (G-CSF): Filgrastim (granulocyte colony-stimulating factor, G-CSF) stimulates neutrophil production and is used to prevent or treat chemotherapy-induced neutropenia. While it reduces the risk of infections, it has no role in increasing platelet counts, making it inappropriate for managing thrombocytopenia.",
      "correct_choice_id": 227392,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/57510871698241315/57510871698241315.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/57510871698241315/57510871698241315.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57523,
      "choices": [
        {
          "id": 227394,
          "text": "Cerebrovascular accident"
        },
        {
          "id": 227395,
          "text": "Prevention of recurrence of myocardial infarction"
        },
        {
          "id": 227396,
          "text": "Retinal artery thrombosis"
        },
        {
          "id": 227397,
          "text": "Prevention of venous thrombosis and pulmonary embolism"
        }
      ],
      "text": "In which of the following clinical conditions does the use of anticoagulants provide maximum benefit",
      "unique_key": "Q2981471",
      "question_audio": null,
      "question_video": null,
      "map_id": 34690207,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Prevention of venous thrombosis and pulmonary embolism. Anticoagulants provide maximum benefit in preventing and treating venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE). Venous thrombi are primarily composed of fibrin and red blood cells, making them highly responsive to anticoagulant therapy. Anticoagulants such as heparin, low-molecular-weight heparin (LMWH), and direct oral anticoagulants (DOACs) effectively prevent clot propagation and reduce the risk of life-threatening PE. In high-risk patients, including those undergoing major surgery, immobilized individuals, and patients with inherited thrombophilias, anticoagulation significantly reduces morbidity and mortality. Incorrect Options: (A) Cerebrovascular accident (CVA or stroke): The use of anticoagulants in stroke depends on the cause. Ischemic stroke due to embolism from atrial fibrillation benefits from anticoagulation (e.g., warfarin, DOACs) to prevent recurrent strokes. However, acute anticoagulation is not routinely recommended for most ischemic strokes because it does not significantly improve outcomes and increases the risk of hemorrhagic transformation. In hemorrhagic stroke, anticoagulants are contraindicated as they can worsen bleeding. (B) Prevention of recurrence of myocardial infarction (MI): Antiplatelet agents (e.g., aspirin, clopidogrel) are the primary drugs used to prevent recurrent MI, as arterial thrombi in coronary arteries are platelet-rich. Anticoagulants are used in select cases, such as MI complicated by left ventricular thrombus or atrial fibrillation, but they are not the first-line therapy for MI recurrence prevention. (C) Retinal artery thrombosis: Retinal artery occlusion is usually caused by embolism rather than thrombosis, making antiplatelet therapy (aspirin) or fibrinolytics more relevant than anticoagulants. There is limited evidence supporting the routine use of anticoagulants in retinal artery thrombosis. Instead, treatment focuses on reducing intraocular pressure and improving retinal perfusion.",
      "correct_choice_id": 227397,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/59484161698241430/59484161698241430.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/59484161698241430/59484161698241430.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57524,
      "choices": [
        {
          "id": 227398,
          "text": "Melagatran"
        },
        {
          "id": 227399,
          "text": "Bivalirudin"
        },
        {
          "id": 227400,
          "text": "Ximelgatran"
        },
        {
          "id": 227401,
          "text": "Argatroban"
        }
      ],
      "text": "Orally acting direct thrombin inhibitor is",
      "unique_key": "Q3305750",
      "question_audio": null,
      "question_video": null,
      "map_id": 34593231,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Ximelgatran. Ximelgatran was the first oral direct thrombin inhibitor (DTI) developed. It is a prodrug that is converted into its active form, melagatran, in the body. As a direct thrombin inhibitor, ximelgatran inhibits both free and clot-bound thrombin, preventing the conversion of fibrinogen to fibrin and reducing thrombus formation. It was initially developed as an alternative to warfarin for anticoagulation. However, ximelgatran was withdrawn from the market due to concerns about hepatotoxicity (elevated liver enzymes and potential liver failure). Despite this, it remains a key historical example of an orally acting direct thrombin inhibitor. Incorrect Options: (A) Melagatran: Melagatran is the active metabolite of ximelgatran and is a direct thrombin inhibitor. However, it is not orally active—it requires parenteral administration. Ximelgatran, the prodrug, is absorbed orally and then converted into melagatran in the body, making ximelgatran the correct choice for an oral thrombin inhibitor. (B) Bivalirudin: Bivalirudin is a parenterally administered direct thrombin inhibitor. It is primarily used during percutaneous coronary interventions (PCI) and in patients with heparin-induced thrombocytopenia (HIT). It is not orally active, making it an incorrect choice. (D) Argatroban: Argatroban is another parenteral direct thrombin inhibitor that is administered intravenously. It is primarily used in the management of heparin-induced thrombocytopenia (HIT). Since it is not orally administered, it is not the correct answer.",
      "correct_choice_id": 227400,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/51999151698241446/51999151698241446.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/51999151698241446/51999151698241446.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57525,
      "choices": [
        {
          "id": 227402,
          "text": "Bretylium"
        },
        {
          "id": 227403,
          "text": "Adenosine"
        },
        {
          "id": 227404,
          "text": "Lidocaine"
        },
        {
          "id": 227405,
          "text": "Warfarin"
        }
      ],
      "text": "Which of the following medications would be prescribed most frequently to patient suffering from chronic atrial fibrillation",
      "unique_key": "Q6345427",
      "question_audio": null,
      "question_video": null,
      "map_id": 34232956,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Warfarin. Chronic atrial fibrillation (AF) significantly increases the risk of thromboembolism, particularly stroke, due to the formation of atrial thrombi. Oral anticoagulation therapy, such as warfarin, is the most frequently prescribed medication to prevent stroke in AF patients, especially those with high CHA?DS?-VASc scores. Warfarin is a vitamin K antagonist that inhibits clotting factors II, VII, IX, and X, reducing the risk of thrombus formation. Though newer direct oral anticoagulants (DOACs) (e.g., dabigatran, rivaroxaban, apixaban) are now preferred due to fewer drug interactions and no need for INR monitoring, warfarin remains a commonly used anticoagulant, especially in patients with mechanical heart valves or severe renal disease. Incorrect Options: (A) Bretylium: Bretylium is an antiarrhythmic agent (Class III potassium channel blocker) primarily used for ventricular arrhythmias, especially in refractory ventricular fibrillation or ventricular tachycardia. It is not indicated for chronic AF management, as it does not address the thromboembolic risk associated with AF. (B) Adenosine: Adenosine is a short-acting antiarrhythmic agent used primarily for supraventricular tachycardia (SVT). It slows conduction through the AV node but has no role in managing chronic AF, as AF originates from abnormal atrial activity rather than AV nodal reentry. (C) Lidocaine: Lidocaine is a Class IB antiarrhythmic drug used mainly for ventricular arrhythmias, particularly in the setting of acute myocardial infarction. It has no role in managing chronic AF, as it does not prevent thromboembolism or effectively control atrial arrhythmias.",
      "correct_choice_id": 227405,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/35524821698241474/35524821698241474.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/35524821698241474/35524821698241474.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57526,
      "choices": [
        {
          "id": 227406,
          "text": "Enoxaparin"
        },
        {
          "id": 227407,
          "text": "Aspirin"
        },
        {
          "id": 227408,
          "text": "Urokinase"
        },
        {
          "id": 227409,
          "text": "Warfarin"
        }
      ],
      "text": "An old woman Nanda suffered stroke for which she was given Alteplase. She improved considerably. To prevent the recurrence of stroke, this patient is most likely to be treated indefinitely with",
      "unique_key": "Q2472355",
      "question_audio": null,
      "question_video": null,
      "map_id": 34257187,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Aspirin. Aspirin is the most commonly prescribed medication for secondary stroke prevention, particularly in cases of non-cardioembolic ischemic stroke. It works by irreversibly inhibiting cyclooxygenase-1 (COX-1), thereby reducing thromboxane A2 production and preventing platelet aggregation. This antiplatelet effect helps reduce the risk of recurrent stroke by preventing thrombus formation in cerebral arteries. Patients who have suffered a non-cardioembolic stroke or transient ischemic attack (TIA) typically receive aspirin (or clopidogrel) indefinitely to prevent further vascular events. Incorrect Options: (A) Enoxaparin: Enoxaparin is a low-molecular-weight heparin (LMWH) used primarily for venous thromboembolism (VTE) prevention and the acute management of certain thrombotic conditions. It is not recommended for long-term secondary stroke prevention because it does not specifically target arterial thrombosis, which is the primary cause of ischemic stroke. (C) Urokinase: Urokinase is a fibrinolytic agent like alteplase (tPA) that is used in acute thrombolysis, not long-term stroke prevention. Using fibrinolytics for extended periods would increase the risk of major bleeding without providing additional benefits in preventing recurrent stroke. (D) Warfarin: Warfarin is an oral anticoagulant used for cardioembolic stroke prevention, particularly in patients with atrial fibrillation, mechanical heart valves, or other high-risk cardiac conditions. Since this patient’s stroke etiology is not specified as cardioembolic, warfarin is not the first-line choice for secondary prevention. Instead, antiplatelet therapy (aspirin or clopidogrel) is preferred for non-cardioembolic stroke.",
      "correct_choice_id": 227407,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/51491001698241488/51491001698241488.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/51491001698241488/51491001698241488.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57527,
      "choices": [
        {
          "id": 227410,
          "text": "Begin therapy with vitamin K"
        },
        {
          "id": 227411,
          "text": "Increase the dosage of warfarin"
        },
        {
          "id": 227412,
          "text": "Make no alterations in the dosage of warfarin"
        },
        {
          "id": 227413,
          "text": "Decrease the dosage of warfarin"
        },
        {
          "id": 227414,
          "text": "Stop the warfarin and change to low-dose aspirin"
        }
      ],
      "text": "Warfarin is administered to a 56-year-old man following placement of a prosthetic cardiac valve. The warfarin dosage is adjusted to maintain an INR of 2.5. Subsequently,trimethoprim-sulfamethoxazole therapy is begun for a recurring urinary tract infection. In addition to monitoring prothrombin time, which of the following actions should the physician take to maintain adequate anticoagulation?",
      "unique_key": "Q4708281",
      "question_audio": null,
      "question_video": null,
      "map_id": 34468912,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Decrease the dosage of warfarin. Warfarin is metabolized primarily by the cytochrome P450 (CYP) enzymes, particularly CYP2C9. Trimethoprim-sulfamethoxazole (TMP-SMX) is a potent inhibitor of CYP2C9, leading to decreased metabolism of warfarin and increased anticoagulant effect. This results in a prolonged prothrombin time (PT) and an elevated INR, increasing the risk of serious bleeding complications. To maintain safe anticoagulation while the patient is on TMP-SMX, the warfarin dosage should be reduced and INR should be closely monitored. Incorrect Options: (A) Begin therapy with vitamin K: Vitamin K antagonizes the anticoagulant effect of warfarin, which would reduce its effectiveness and increase the risk of thromboembolism, especially in a patient with a prosthetic cardiac valve. This is not the correct strategy unless the patient is experiencing life-threatening bleeding due to excessive anticoagulation. (B) Increase the dosage of warfarin: Since TMP-SMX inhibits warfarin metabolism, increasing the dose would further elevate INR and increase bleeding risk. Instead, the correct approach is to reduce the dose. (C) Make no alterations in the dosage of warfarin: Failing to adjust the warfarin dose in a patient starting TMP-SMX could lead to dangerously high INR levels and an increased risk of major bleeding. Regular INR monitoring and dose adjustments are necessary. (E) Stop the warfarin and change to low-dose aspirin: Aspirin is not a suitable replacement for warfarin in a patient with a prosthetic cardiac valve, as it does not provide sufficient anticoagulation. Mechanical heart valves require long-term warfarin therapy to prevent thromboembolism, and stopping warfarin in favor of aspirin would significantly increase the risk of valve thrombosis and stroke.",
      "correct_choice_id": 227413,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/71447451698241564/71447451698241564.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/71447451698241564/71447451698241564.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57528,
      "choices": [
        {
          "id": 227415,
          "text": "Sulfinpyrazone"
        },
        {
          "id": 227416,
          "text": "Dipyridamole"
        },
        {
          "id": 227417,
          "text": "ticlopidine"
        },
        {
          "id": 227418,
          "text": "Abciximab"
        }
      ],
      "text": "This drug can potentiate the effect of prostacyclin to antagonize platelet stickiness and therefore decreases platelet adhesion to thrombogenic surfaces.",
      "unique_key": "Q4640728",
      "question_audio": null,
      "question_video": null,
      "map_id": 34590730,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Dipyridamole. Dipyridamole is an antiplatelet agent that potentiates the effect of prostacyclin (PGI?), which inhibits platelet aggregation and promotes vasodilation. It works by inhibiting phosphodiesterase (PDE), leading to increased cyclic AMP (cAMP) levels in platelets, thereby reducing platelet activation. Additionally, dipyridamole inhibits adenosine uptake by platelets, increasing extracellular adenosine, which further stimulates adenylate cyclase and raises intracellular cAMP levels, leading to an overall antiplatelet effect. This mechanism helps decrease platelet adhesion to thrombogenic surfaces, making dipyridamole useful in stroke prevention and as an adjunct to warfarin in prosthetic heart valve patients. Incorrect Options: (A) Sulfinpyrazone: Sulfinpyrazone is a uricosuric drug primarily used to treat gout by increasing uric acid excretion. However, it also has some antiplatelet effects by inhibiting platelet cyclooxygenase (COX), thereby reducing thromboxane A? synthesis. Unlike dipyridamole, sulfinpyrazone does not potentiate prostacyclin or significantly affect platelet adhesion to thrombogenic surfaces. (C) Ticlopidine: Ticlopidine is a thienopyridine-class antiplatelet agent that works by irreversibly inhibiting the P2Y?? receptor on platelets, preventing ADP-induced platelet aggregation. While ticlopidine is effective in reducing platelet aggregation, it does not potentiate prostacyclin activity. Additionally, ticlopidine has been largely replaced by clopidogrel due to its risk of neutropenia and thrombotic thrombocytopenic purpura (TTP). (D) Abciximab: Abciximab is a glycoprotein IIb/IIIa (GpIIb/IIIa) receptor antagonist that directly blocks platelet aggregation by preventing fibrinogen binding to activated platelets. It is primarily used in percutaneous coronary interventions (PCI) to prevent thrombosis. However, it does not enhance prostacyclin effects or reduce platelet adhesion through the cAMP pathway like dipyridamole does.",
      "correct_choice_id": 227416,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/66534301698241659/66534301698241659.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/66534301698241659/66534301698241659.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57529,
      "choices": [
        {
          "id": 227419,
          "text": "It blocks Gp1ib/Ma receptors on platelet membrane"
        },
        {
          "id": 227420,
          "text": "It does not prolong bleeding time"
        },
        {
          "id": 227421,
          "text": "It inhibits thromboxane A2 synthesis in platelets"
        },
        {
          "id": 227422,
          "text": "It prevents ADP mediated platelet adenylyl cyclase inhibition"
        }
      ],
      "text": "Which of the following statements regarding ticlopidine is TRUE?",
      "unique_key": "Q1461548",
      "question_audio": null,
      "question_video": null,
      "map_id": 34587897,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) It prevents ADP mediated platelet adenylyl cyclase inhibition. Ticlopidine is an antiplatelet drug that works by inhibiting the binding of ADP (adenosine diphosphate) to its receptor (P2Y12) on platelets. This inhibition prevents the ADP-mediated inhibition of platelet adenylyl cyclase, which in turn reduces platelet aggregation. By doing so, it helps to prevent the formation of blood clots, particularly in patients at risk of stroke or other thrombotic events. Incorrect options: A. It blocks Gp1b/IX/V receptors on platelet membrane: This statement is incorrect because ticlopidine does not directly block the Gp1b/IX/V receptors, which are involved in the initial adhesion of platelets to the damaged blood vessel wall. Ticlopidine primarily acts on the ADP receptor (P2Y12) to prevent platelet aggregation, not through the Gp1b complex. B. It does not prolong bleeding time: This statement is false. Ticlopidine does indeed prolong bleeding time as it inhibits platelet aggregation. Like other antiplatelet drugs, it can increase the time it takes for blood to clot. C. It inhibits thromboxane A2 synthesis in platelets: This is incorrect. Ticlopidine does not inhibit thromboxane A2 synthesis. Thromboxane A2 is typically inhibited by drugs like aspirin, which block cyclooxygenase (COX) enzymes responsible for its production. Ticlopidine works by blocking the ADP receptor, not by inhibiting thromboxane A2.",
      "correct_choice_id": 227422,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/49882021698479969/49882021698479969.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/49882021698479969/49882021698479969.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57530,
      "choices": [
        {
          "id": 227423,
          "text": "ls more likely to cause formation of antiplatelet antibodies"
        },
        {
          "id": 227424,
          "text": "Has a greater antiplatelet effect"
        },
        {
          "id": 227425,
          "text": "Is more likely to cause severe bleeding"
        },
        {
          "id": 227426,
          "text": "Is less likely to cause neutropenia"
        }
      ],
      "text": "With respect to ticlopidine, clopidogrel",
      "unique_key": "Q3937604",
      "question_audio": null,
      "question_video": null,
      "map_id": 34133949,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Clopidogrel is less likely to cause neutropenia. Clopidogrel and ticlopidine are both thienopyridine antiplatelet agents that inhibit the P2Y12 receptor on platelets, thereby preventing platelet aggregation. However, ticlopidine is associated with a higher risk of hematological adverse effects, including neutropenia and thrombotic thrombocytopenic purpura (TTP), whereas clopidogrel has a significantly lower incidence of these complications. Due to its better safety profile, clopidogrel has largely replaced ticlopidine in clinical practice. Neutropenia with ticlopidine can be severe and requires regular blood monitoring, whereas clopidogrel rarely causes this adverse effect. Explanation of Incorrect Options: (A) Clopidogrel is more likely to cause the formation of antiplatelet antibodies – Incorrect. Both ticlopidine and clopidogrel inhibit platelet aggregation, but neither is strongly associated with inducing antiplatelet antibodies. However, ticlopidine has been linked to thrombotic thrombocytopenic purpura (TTP), which involves the formation of autoantibodies against ADAMTS13, a protease involved in platelet regulation. Clopidogrel has a much lower incidence of TTP and does not significantly increase the risk of antibody formation. (B) Clopidogrel has a greater antiplatelet effect – Incorrect. Ticlopidine and clopidogrel both act by irreversibly inhibiting the P2Y12 receptor, but clopidogrel does not have a significantly greater antiplatelet effect than ticlopidine. The efficacy of both drugs in preventing platelet aggregation is comparable, but clopidogrel is preferred due to its faster onset of action, better tolerability, and lower risk of hematologic side effects. (C) Clopidogrel is more likely to cause severe bleeding – Incorrect. Both drugs increase the risk of bleeding as they inhibit platelet aggregation, but clopidogrel is not significantly more likely to cause severe bleeding than ticlopidine. In fact, ticlopidine may have a slightly higher bleeding risk due to its association with hematologic disorders such as neutropenia and TTP. Clopidogrel is generally well tolerated and has a more favorable safety profile, making it the preferred agent.",
      "correct_choice_id": 227426,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/5290081698480069/5290081698480069.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/5290081698480069/5290081698480069.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57531,
      "choices": [
        {
          "id": 227427,
          "text": "Abciximab"
        },
        {
          "id": 227428,
          "text": "Argatroban"
        },
        {
          "id": 227429,
          "text": "Plasminogen"
        },
        {
          "id": 227430,
          "text": "Urokinase"
        }
      ],
      "text": "A patient develops severe thrombocytopenia after 10 days of treatment with unfractionated heparin that is started after a surgery for deep vein thrombosis.. What is best management for the complication developed in above patient",
      "unique_key": "Q6910899",
      "question_audio": null,
      "question_video": null,
      "map_id": 34557859,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Argatroban. The patient in the scenario has developed severe thrombocytopenia after unfractionated heparin (UFH) therapy, which is indicative of heparin-induced thrombocytopenia (HIT). HIT is an immune-mediated reaction that leads to a decrease in platelet count and an increased risk of thrombosis. In cases of HIT, the use of UFH must be discontinued immediately, and an alternative anticoagulant should be started. Argatroban is a direct thrombin inhibitor that is used as an alternative anticoagulant in patients with HIT. It directly inhibits thrombin and does not interact with platelet factor 4 (PF4) or heparin, thus providing safe anticoagulation in HIT patients. Argatroban is often used in patients with renal impairment and active HIT, and it can be used until platelet counts recover and the risk of thrombosis is reduced. Explanation of Incorrect Options: (A) Abciximab – Incorrect. Abciximab is a glycoprotein IIb/IIIa inhibitor used in the management of acute coronary syndrome and during percutaneous coronary interventions to prevent thrombosis. While it inhibits platelet aggregation, it is not indicated for the treatment of HIT. In fact, using abciximab in HIT may increase the risk of bleeding and thrombosis, so it is not an appropriate treatment for this condition. (C) Plasminogen – Incorrect. Plasminogen is a precursor of plasmin, which is involved in the breakdown of fibrin (fibrinolysis). It is used in the management of thrombolytic therapy for conditions like acute myocardial infarction or stroke, but it does not treat HIT. HIT is a thrombotic disorder, and plasminogen would not address the underlying platelet activation or thrombosis seen in this condition. (D) Urokinase – Incorrect. Urokinase is a fibrinolytic agent that helps to dissolve clots by activating plasminogen to plasmin. It is used for thrombolysis in conditions like pulmonary embolism or deep vein thrombosis (DVT) but is not indicated for the treatment of HIT. In fact, giving urokinase in HIT could increase the risk of bleeding and worsen the thrombosis, so it is not appropriate for this patient.",
      "correct_choice_id": 227428,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/64984181700305279/64984181700305279.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/64984181700305279/64984181700305279.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57532,
      "choices": [
        {
          "id": 227431,
          "text": "Abciximab"
        },
        {
          "id": 227432,
          "text": "Alteplase"
        },
        {
          "id": 227433,
          "text": "Factor VIII"
        },
        {
          "id": 227434,
          "text": "Streptokinase"
        }
      ],
      "text": "A 65-year-old man is brought to the emergency room 30 min after the onset of right-sided weakness and aphasia (difficulty speaking). Imaging studies ruled out cerebral hemorrhage as the cause of his acute symptoms of stroke. Prompt administration of which of the following drugs is most likely to improve this patient's clinical outcome?",
      "unique_key": "Q4662493",
      "question_audio": null,
      "question_video": null,
      "map_id": 34834443,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Alteplase. This patient has acute ischemic stroke, as indicated by the right-sided weakness and aphasia. Imaging has ruled out cerebral hemorrhage, which suggests that this stroke is ischemic (caused by a clot blocking blood flow to the brain). The most effective treatment for acute ischemic stroke within 3 to 4.5 hours of symptom onset is thrombolytic therapy with alteplase. Alteplase is a recombinant tissue plasminogen activator (rtPA) that works by breaking down the clot and restoring blood flow to the affected brain tissue. It is shown to significantly improve clinical outcomes when administered promptly, making it the best choice for this patient. Explanation of Incorrect Options: (A) Abciximab – Incorrect. Abciximab is a glycoprotein IIb/IIIa inhibitor used primarily in the treatment of acute coronary syndrome and during percutaneous coronary interventions (PCI). While it works by inhibiting platelet aggregation, it is not used for ischemic stroke. Abciximab does not address the fibrinolysis needed to break down the clot in the brain, which is why alteplase is preferred for ischemic stroke management. (C) Factor VIII – Incorrect. Factor VIII is used in the treatment of hemophilia A, a bleeding disorder caused by a deficiency in clotting factor VIII. It is not indicated for the treatment of ischemic stroke. Factor VIII would not aid in dissolving the clot in the brain and would not improve the patient's clinical outcome in this context. (D) Streptokinase – Incorrect. Streptokinase is an older thrombolytic agent that was used for the treatment of acute myocardial infarction and pulmonary embolism. However, it has largely been replaced by alteplase due to its lower efficacy and higher risk of allergic reactions and bleeding complications. Streptokinase is not preferred for acute ischemic stroke because alteplase is more effective and safer in this setting.",
      "correct_choice_id": 227432,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/64013311700305295/64013311700305295.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/64013311700305295/64013311700305295.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57533,
      "choices": [
        {
          "id": 227435,
          "text": "To lower blood pressure"
        },
        {
          "id": 227436,
          "text": "To reduce cholesterol levels"
        },
        {
          "id": 227437,
          "text": "To prevent thromboembolism"
        },
        {
          "id": 227438,
          "text": "To increase heart rate"
        }
      ],
      "text": "A patient with atrial fibrillation is prescribed warfarin. What is the primary goal of warfarin therapy?",
      "unique_key": "Q7654954",
      "question_audio": null,
      "question_video": null,
      "map_id": 34874731,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) To prevent thromboembolism. Warfarin is an oral anticoagulant that works by inhibiting vitamin K-dependent clotting factors (II, VII, IX, and X), thereby reducing the risk of thrombus (clot) formation. In atrial fibrillation (AF), blood stasis in the atria, particularly the left atrial appendage, increases the risk of thromboembolism, which can lead to stroke or systemic embolism. Warfarin helps prevent these complications by reducing the formation of fibrin-rich thrombi, making it a key component of stroke prevention in patients with AF who have additional risk factors (e.g., CHA2DS2-VASc score ≥ 2). Regular INR (International Normalized Ratio) monitoring is required to ensure therapeutic anticoagulation (typically target INR 2.0–3.0). Explanation of Incorrect Options: (A) To lower blood pressure – Incorrect. Warfarin has no direct effect on blood pressure. Hypertension is managed with antihypertensive drugs like beta-blockers, ACE inhibitors, or calcium channel blockers. However, uncontrolled hypertension increases the risk of bleeding complications in patients on warfarin therapy. (B) To reduce cholesterol levels – Incorrect. Warfarin does not affect cholesterol metabolism. Statins (e.g., atorvastatin, rosuvastatin) are the primary drugs used for lowering cholesterol and preventing atherosclerotic cardiovascular disease (ASCVD). While hyperlipidemia is a risk factor for stroke, warfarin’s role is solely in preventing thromboembolism, not lipid reduction. (D) To increase heart rate – Incorrect. Warfarin has no effect on heart rate. In atrial fibrillation, rate control is typically managed with beta-blockers (e.g., metoprolol), calcium channel blockers (e.g., diltiazem), or digoxin. Warfarin is used only for stroke prevention in AF and does not influence heart rate or rhythm control.",
      "correct_choice_id": 227437,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/53496641727681006/53496641727681006.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/53496641727681006/53496641727681006.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57534,
      "choices": [
        {
          "id": 227439,
          "text": "Warfarin"
        },
        {
          "id": 227440,
          "text": "Dabigatran"
        },
        {
          "id": 227441,
          "text": "Rivaroxaban"
        },
        {
          "id": 227442,
          "text": "Apixaban"
        }
      ],
      "text": "A 72-year-old woman with a history of atrial fibrillation and a recent stroke is started on a new anticoagulant. She is concerned about potential dietary restrictions with her new medication. Which of the following medications is likely to require dietary modifications or monitoring?",
      "unique_key": "Q1838823",
      "question_audio": null,
      "question_video": null,
      "map_id": 34266488,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Warfarin. Warfarin is a vitamin K antagonist that works by inhibiting the synthesis of vitamin K-dependent clotting factors. One of the key considerations with warfarin therapy is that dietary modifications are necessary due to its interaction with vitamin K-rich foods (such as green leafy vegetables). These foods can counteract warfarin's effects by increasing vitamin K levels, which may reduce the anticoagulant effect. As a result, patients on warfarin must maintain a consistent intake of vitamin K and have their INR levels monitored regularly to ensure appropriate anticoagulation. So, while warfarin requires monitoring and potential dietary adjustments, it is more prone to dietary interactions than the newer anticoagulants. Explanation of Incorrect Options: (B) Dabigatran – Incorrect. Dabigatran is a direct thrombin inhibitor and is one of the newer non-vitamin K antagonist oral anticoagulants (NOACs). Unlike warfarin, dabigatran does not require monitoring of INR and has no dietary restrictions related to vitamin K. However, dabigatran can interact with certain medications (such as P-glycoprotein inhibitors), and it may require dose adjustments in patients with renal dysfunction. While there are fewer dietary concerns with dabigatran compared to warfarin, it still carries some interactions that need to be considered. (C) Rivaroxaban – Incorrect. Rivaroxaban is another NOAC that directly inhibits factor Xa. Similar to dabigatran, rivaroxaban does not require regular INR monitoring and has no dietary restrictions like warfarin does. However, rivaroxaban can also be affected by other medications (e.g., CYP3A4 inhibitors or inducers) and renal function, which may require dose adjustments. Despite not needing dietary modifications, rivaroxaban carries similar concerns related to drug interactions and renal function that patients need to be aware of. (D) Apixaban – Incorrect. Apixaban is another direct factor Xa inhibitor like rivaroxaban. It also does not require regular INR monitoring and has no dietary restrictions related to vitamin K. However, as with rivaroxaban and dabigatran, apixaban can interact with CYP3A4 inhibitors/inducers and renal function. While it is considered to have a more favorable side effect profile compared to warfarin, it still carries potential interaction concerns, particularly in patients with renal impairment or those on other medications that affect its metabolism.",
      "correct_choice_id": 227439,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/77283711727681297/77283711727681297.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/77283711727681297/77283711727681297.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57535,
      "choices": [
        {
          "id": 227443,
          "text": "Leafy green vegetables"
        },
        {
          "id": 227444,
          "text": "Citrus fruits"
        },
        {
          "id": 227445,
          "text": "Dairy products"
        },
        {
          "id": 227446,
          "text": "Lean meats"
        }
      ],
      "text": "A 68-year-old man with a history of chronic atrial fibrillation and heart failure is being managed on warfarin. He is advised to follow a strict diet and to avoid certain foods. Which of the following foods should he particularly avoid or consistently moderate to prevent fluctuations in INR levels?",
      "unique_key": "Q4617040",
      "question_audio": null,
      "question_video": null,
      "map_id": 34456272,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Leafy green vegetables. Patients on warfarin are required to avoid large fluctuations in their vitamin K intake, as vitamin K directly influences the effectiveness of warfarin, which works by inhibiting the vitamin K-dependent clotting factors. Leafy green vegetables (such as spinach, kale, collard greens, and broccoli) are rich in vitamin K, and consuming large amounts of these foods can counteract the effects of warfarin, leading to fluctuations in the INR (International Normalized Ratio) and potentially causing blood clotting issues or bleeding complications. Therefore, patients on warfarin should maintain consistent intake of these vegetables to prevent significant changes in INR levels. Explanation of Incorrect Options: (B) Citrus fruits – Incorrect. Citrus fruits (such as oranges, grapefruits, and lemons) do not have a significant impact on warfarin's effect or INR levels. While grapefruit can interact with certain medications by inhibiting enzymes involved in their metabolism, this is not a primary concern with warfarin. Citrus fruits are generally safe to consume while on warfarin, as long as the diet is balanced and does not involve excessive amounts of any single food group. (C) Dairy products – Incorrect. Dairy products (such as milk, cheese, and yogurt) do not directly affect warfarin's action or cause significant fluctuations in INR levels. While calcium in dairy may interact with some medications, it does not significantly influence warfarin's anticoagulant effect. However, patients should be mindful of a balanced diet, but dairy products are generally safe in moderate amounts for patients taking warfarin. (D) Lean meats – Incorrect. Lean meats (such as chicken, turkey, and fish) do not have any significant impact on warfarin therapy or INR levels. They are a good source of protein but do not interact with warfarin in a way that requires special dietary precautions. Therefore, lean meats can be safely included in the diet without affecting the efficacy of warfarin.",
      "correct_choice_id": 227443,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/37887781727682365/37887781727682365.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/37887781727682365/37887781727682365.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57536,
      "choices": [
        {
          "id": 227447,
          "text": "Amoxicillin"
        },
        {
          "id": 227448,
          "text": "Acetaminophen"
        },
        {
          "id": 227449,
          "text": "Ibuprofen"
        },
        {
          "id": 227450,
          "text": "Metformin"
        }
      ],
      "text": "A 62-year-old man with a history of atrial fibrillation is started on warfarin. After a few months, he develops a new condition that requires him to start a new medication. Which of the following new medications is most likely to require careful consideration due to potential interactions with warfarin?",
      "unique_key": "Q1997845",
      "question_audio": null,
      "question_video": null,
      "map_id": 34053282,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Ibuprofen. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that can significantly interact with warfarin. NSAIDs like ibuprofen can increase the risk of bleeding when taken with warfarin, because they can inhibit platelet aggregation and affect the gastric mucosa, which may lead to gastric ulcers and bleeding. Additionally, NSAIDs can alter kidney function, potentially affecting warfarin metabolism and increasing the INR, which could lead to increased anticoagulation and a higher risk of bleeding. Therefore, careful consideration is needed when prescribing ibuprofen to a patient already on warfarin. Explanation of Incorrect Options: (A) Amoxicillin – Incorrect. Amoxicillin, an antibiotic, has minimal interaction with warfarin. Although antibiotics can sometimes affect the intestinal flora and Vitamin K production, the interaction between amoxicillin and warfarin is generally mild and does not pose a significant risk for bleeding or changes in INR. The primary concern would be a potential for infection or a reduction in gut flora, but it does not require special adjustments to warfarin therapy. (B) Acetaminophen – Incorrect. Acetaminophen is generally considered safe in patients taking warfarin when used in moderate doses. However, high doses of acetaminophen can increase the risk of bleeding by affecting the liver's production of clotting factors. The interaction is minimal at normal therapeutic doses, and occasional use of acetaminophen does not require dose adjustments for warfarin. (D) Metformin – Incorrect. Metformin is an oral medication for diabetes that does not interact with warfarin. It works by reducing hepatic glucose production and increasing insulin sensitivity, and does not have a significant effect on coagulation parameters or INR. Therefore, it does not require careful consideration or adjustment when used in combination with warfarin.",
      "correct_choice_id": 227449,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/17319691727682380/17319691727682380.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/17319691727682380/17319691727682380.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57537,
      "choices": [
        {
          "id": 227451,
          "text": "Administration of vitamin K"
        },
        {
          "id": 227452,
          "text": "Fresh frozen plasma (FFP)"
        },
        {
          "id": 227453,
          "text": "Prothrombin complex concentrate (PCC)"
        },
        {
          "id": 227454,
          "text": "Discontinuation of warfarin"
        }
      ],
      "text": "A 70-year-old woman with a history of atrial fibrillation is on warfarin therapy for stroke prevention. She presents to the emergency department with a major gastrointestinal bleed. What is the most appropriate immediate treatment for her condition?",
      "unique_key": "Q3122086",
      "question_audio": null,
      "question_video": null,
      "map_id": 34857500,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Prothrombin Complex Concentrate (PCC). PCC is the most effective and rapid treatment for reversing warfarin-induced anticoagulation in life-threatening bleeding events, such as a major gastrointestinal (GI) bleed. PCC contains clotting factors II, VII, IX, and X, which are vitamin K-dependent factors that are depleted due to warfarin therapy. Administration of PCC rapidly restores coagulation and reduces bleeding risk within minutes, making it the preferred option in emergencies. In contrast, vitamin K alone takes several hours to act, as it requires hepatic synthesis of new clotting factors. Incorrect Options: (A) Administration of vitamin K: While vitamin K (phytonadione) is essential for long-term warfarin reversal, it has a delayed onset of action (4–6 hours intravenously and up to 24 hours orally). In cases of life-threatening bleeding, relying solely on vitamin K is inadequate because immediate clotting factor replacement is needed, which is why PCC is preferred. However, vitamin K is often administered along with PCC to ensure sustained reversal of warfarin’s effects. (B) Fresh Frozen Plasma (FFP): FFP contains all coagulation factors, including those depleted by warfarin, but it has several disadvantages compared to PCC. It requires large volumes for effective reversal, which may lead to fluid overload, especially in elderly patients or those with heart failure. Additionally, FFP takes longer to thaw and administer compared to PCC. While it can be used if PCC is unavailable, PCC remains the first-line treatment due to its rapid and targeted action. (D) Discontinuation of warfarin: Simply stopping warfarin is not sufficient in an emergency situation, as warfarin has a long half-life (approximately 36–42 hours), and its anticoagulant effects persist for several days. Immediate reversal with PCC is necessary to control active bleeding, making discontinuation alone an inadequate intervention.",
      "correct_choice_id": 227453,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/37113601727676358/37113601727676358.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/37113601727676358/37113601727676358.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57538,
      "choices": [
        {
          "id": 227455,
          "text": "Apixaban"
        },
        {
          "id": 227456,
          "text": "Rivaroxaban"
        },
        {
          "id": 227457,
          "text": "Edoxaban"
        },
        {
          "id": 227458,
          "text": "Dabigatran"
        }
      ],
      "text": "A 50-year-old female with a history of deep vein thrombosis (DVT) is started on a direct oral anticoagulant (DOAC) for long-term anticoagulation. After six months, she presents with an unexplained increase in liver enzymes. Which of the following DOACs is most likely associated with hepatotoxicity?",
      "unique_key": "Q2755298",
      "question_audio": null,
      "question_video": null,
      "map_id": 34766209,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Rivaroxaban. Among the direct oral anticoagulants (DOACs), rivaroxaban has been most commonly associated with hepatotoxicity, including elevations in liver transaminases (AST/ALT) and, in rare cases, drug-induced liver injury (DILI). This hepatotoxicity is thought to be due to idiosyncratic liver reactions rather than a dose-dependent effect. Rivaroxaban is a factor Xa inhibitor, and although it is generally well tolerated, cases of liver enzyme elevation and even severe hepatotoxicity have been reported, especially within the first six months of therapy. Patients on rivaroxaban should have periodic liver function monitoring, particularly if they have underlying liver disease or develop symptoms suggestive of liver dysfunction. Incorrect Options: (A) Apixaban: Apixaban is another factor Xa inhibitor, but it has a lower risk of hepatotoxicity compared to rivaroxaban. Studies suggest that apixaban has a more favorable hepatic safety profile, with minimal liver enzyme elevations reported in clinical trials. Unlike rivaroxaban, cases of severe liver injury are extremely rare with apixaban. (C) Edoxaban: Edoxaban, also a factor Xa inhibitor, has not been strongly associated with hepatotoxicity. While mild liver enzyme elevations have been noted in some patients, it is not known to cause significant liver injury or failure. (D) Dabigatran: Dabigatran is a direct thrombin (Factor IIa) inhibitor and is not associated with significant hepatotoxicity. It is primarily eliminated by the kidneys, making liver toxicity uncommon. In fact, dabigatran was developed in part due to concerns about liver toxicity observed with its predecessor, ximelagatran, which was withdrawn from the market due to severe liver injury.",
      "correct_choice_id": 227456,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/4481711727676376/4481711727676376.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/4481711727676376/4481711727676376.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57539,
      "choices": [
        {
          "id": 227459,
          "text": "Oral vitamin K"
        },
        {
          "id": 227460,
          "text": "Prothrombin complex concentrate (PCC)"
        },
        {
          "id": 227461,
          "text": "Fresh frozen plasma (FFP)"
        },
        {
          "id": 227462,
          "text": "Discontinue warfarin and monitor"
        }
      ],
      "text": "A 72-year-old man with a history of atrial fibrillation is treated with warfarin. His INR is consistently above the therapeutic range, and he develops a large hematoma after a minor fall. Which of the following treatment is most appropriate to reverse his anticoagulation?",
      "unique_key": "Q9054627",
      "question_audio": null,
      "question_video": null,
      "map_id": 34559005,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Prothrombin Complex Concentrate (PCC). PCC is the most effective and rapid method for reversing warfarin-induced anticoagulation, particularly in cases of serious bleeding, such as a large hematoma. PCC contains vitamin K-dependent clotting factors (II, VII, IX, and X), which are directly depleted by warfarin. It works almost immediately after administration, rapidly restoring coagulation and preventing further bleeding. Given that this patient has an elevated INR and significant bleeding, PCC is the first-line treatment for immediate warfarin reversal. Intravenous vitamin K is often co-administered with PCC to ensure a sustained reversal of warfarin's effects. Incorrect Options: (A) Oral vitamin K: While vitamin K is essential for warfarin reversal, oral vitamin K takes several hours to work (typically 12–24 hours) because it requires the liver to synthesize new clotting factors. In an emergency situation with active bleeding, oral vitamin K alone is insufficient. Instead, PCC is required for immediate correction of INR, while vitamin K can be used concurrently for long-term correction. (C) Fresh Frozen Plasma (FFP): FFP contains all coagulation factors, similar to PCC, but it has several disadvantages. It requires a large volume (which can lead to fluid overload), takes time to thaw and administer, and is not as effective as PCC in rapidly restoring clotting function. PCC is preferred over FFP due to its faster action and lower volume requirements. However, FFP may be used if PCC is unavailable. (D) Discontinue warfarin and monitor: Simply stopping warfarin is insufficient in cases of life-threatening or serious bleeding, as warfarin has a long half-life (36–42 hours) and its effects persist for days. Immediate reversal is required to prevent further bleeding, making PCC the best option. Monitoring alone would be appropriate for minor INR elevations without bleeding, but not for a large hematoma with an elevated INR.",
      "correct_choice_id": 227460,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/54204441727676404/54204441727676404.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/54204441727676404/54204441727676404.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57540,
      "choices": [
        {
          "id": 227463,
          "text": "Metoprolol"
        },
        {
          "id": 227464,
          "text": "Omeprazole"
        },
        {
          "id": 227465,
          "text": "Amiodarone"
        },
        {
          "id": 227466,
          "text": "Ketoconazole"
        }
      ],
      "text": "A 45-year-old male with a history of venous thromboembolism is initiated on rivaroxaban. He inquires about potential drug interactions. Which of the following medications, if prescribed, would most likely increase the risk of bleeding when taken with rivaroxaban?",
      "unique_key": "Q3625547",
      "question_audio": null,
      "question_video": null,
      "map_id": 34142458,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Ketoconazole. Ketoconazole is a strong inhibitor of CYP3A4 and P-glycoprotein (P-gp), both of which are involved in the metabolism and elimination of rivaroxaban. Inhibition of these pathways leads to increased plasma concentrations of rivaroxaban, significantly raising the risk of bleeding. Since rivaroxaban is a direct Factor Xa inhibitor, elevated levels can lead to excessive anticoagulation, making patients more prone to serious hemorrhagic complications such as gastrointestinal (GI) bleeding and intracranial hemorrhage. Incorrect Options: (A) Metoprolol: Metoprolol is a beta-blocker used for hypertension and heart conditions. It is not a significant inhibitor or inducer of CYP3A4 or P-gp, meaning it does not affect rivaroxaban metabolism. Therefore, it does not increase the risk of bleeding. (B) Omeprazole: Omeprazole is a proton pump inhibitor (PPI) used to reduce stomach acid. While PPIs can alter the pH-dependent absorption of some drugs, rivaroxaban is not significantly affected by changes in gastric acidity. Omeprazole does not interact with CYP3A4 or P-gp in a way that would increase rivaroxaban levels, so it does not raise the risk of bleeding. (C) Amiodarone: Amiodarone is an antiarrhythmic drug that has some moderate inhibitory effects on CYP3A4 and P-gp. However, the interaction is not strong enough to significantly raise rivaroxaban levels to a dangerous degree. While it may modestly increase bleeding risk, the effect is much weaker compared to ketoconazole.",
      "correct_choice_id": 227466,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/12877421727676461/12877421727676461.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/12877421727676461/12877421727676461.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57541,
      "choices": [
        {
          "id": 227467,
          "text": "Inhibiting platelet aggregation"
        },
        {
          "id": 227468,
          "text": "Stimulating the production of thrombopoietin"
        },
        {
          "id": 227469,
          "text": "Directly stimulating megakaryocyte production"
        },
        {
          "id": 227470,
          "text": "Enhancing the absorption of dietary iron"
        }
      ],
      "text": "A 75-year-old woman receiving chemotherapy for breast cancer develops thrombocytopenia. She is given a dose of romiplostim to stimulate platelet production. Which of the following mechanisms of action does romiplostim employ?",
      "unique_key": "Q5914785",
      "question_audio": null,
      "question_video": null,
      "map_id": 34782864,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Directly stimulating megakaryocyte production. Romiplostim is a thrombopoietin receptor agonist (TPO-RA) that mimics the effects of endogenous thrombopoietin (TPO). It binds to and activates the TPO receptor (c-Mpl) on hematopoietic stem cells and megakaryocyte precursors, leading to increased proliferation and differentiation of megakaryocytes. This results in an increased platelet production, making it useful for treating chemotherapy-induced thrombocytopenia and immune thrombocytopenia (ITP). Incorrect Options: (A) Inhibiting platelet aggregation: This option is incorrect because romiplostim does not inhibit platelet function. Drugs like aspirin, clopidogrel, and abciximab work by preventing platelet aggregation, reducing clot formation. Romiplostim, in contrast, enhances platelet production rather than altering platelet function. (B) Stimulating the production of thrombopoietin: Romiplostim does not increase endogenous thrombopoietin (TPO) production. Instead, it acts as a synthetic thrombopoietin receptor agonist, directly stimulating the c-Mpl receptor on megakaryocyte precursors. (D) Enhancing the absorption of dietary iron: Romiplostim has no role in iron metabolism or absorption. Iron absorption is primarily regulated by hepcidin and ferroportin, and conditions like iron-deficiency anemia require iron supplementation, not romiplostim. Drugs like ferrous sulfate or ferric carboxymaltose are used for increasing iron absorption, not thrombopoiesis.",
      "correct_choice_id": 227469,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/56824131727676479/56824131727676479.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/56824131727676479/56824131727676479.m3u8",
      "question_images": [],
      "explanation_images": []
    }
  ]
}